|Articles|June 1, 2017

Patheon

A Healthier World. Delivered.
Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. Over the last 10 years, Patheon has supported the delivery of 112 NDA-approved drugs-more than 2.5x the nearest competitor, and as many as the next six leading CMOs combined.

Products and Services
We provide a comprehensive, integrated and highly customizable range of active pharmaceutical ingredient, or API, and finished drug product services to our customers. From formulation development to clinical and commercial-scale manufacturing, packaging, and life-cycle management, our services support both small molecule and large molecule drugs.

Patheon
BIO International Booth #1011

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

November 4th, 2026

The Promise of Microgravity for R&D and Manufacturing

As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.

Hand inserts a molecule into DNA. | Image credit: © natali_mis - © natali_mis - stock.adobe.com

November 4th, 2026

Aldevron, IDT Launch Base and Prime Editing mRNAs for Gene Editing

Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.

Close-up of an older person’s hands with several finger joints highlighted in red, against a white background. | Image Credit: © doucefleur - stock.adobe.com

November 4th, 2026

Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa

The half-life-extended antibody failed its primary endpoints in two Phase 2 SKYWAY sub-studies, so Spyre is dropping it in rheumatic diseases and moving it into a combination trial in hidradenitis suppurativa.

white pill capsule isolated on white background | Image credit: © F16-ISO100 - © F16-ISO100 - stock.adobe.com

November 4th, 2026

Biora Wins Ethics Approval for First Human Trial of BioJet Capsule

Biora will test oral adalimumab via its BioJet capsule vs injection in healthy volunteers, with dosing from December 2026 and data in early 2027.

3D illustration of several small, round gray-green immune cells clustered around and on top of a large purple cancer cell with long branching projections, against a dark red background. | Image Credit: © PRB ARTS - stock.adobe.com

November 4th, 2026

Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion

Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near-term for options on six biologic oncology programs, deepening a partnership that began in 2024.

Exterior of the US Treasury Department building in Washington, DC, with columns along its facade. | Image Credit: © Zack Frank - stock.adobe.com

November 4th, 2026

Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule

A former CIA officer, Pacific Research Institute economists, and industry groups say Treasury's proposed COINS Act biotechnology restrictions are too broad, while the National Security Commission on Emerging Biotechnology backs the move. Comments are due December 7, 2026.

Various of international money coin and banknote with blurred hourglass in the background. Time investment with currency exchange concept. Focus on dollar banknote. | Image credit: © zephyr_p - © zephyr_p - stock.adobe.com

November 3rd, 2026

Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India

Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.

November 3rd, 2026

The BioPharm Brief: A Potency Rulebook, a CDMO Buyout, and a Nasal Antibody for MS

Today’s BioPharm Brief covers FDA’s final potency assurance guidance for cell and gene therapies, Lonza’s deal to acquire Merck KGaA’s US CDMO business, and Phase 2a data for Tiziana’s intranasal anti-CD3 antibody foralumab in progressive multiple sclerosis.

Patheon

Related to this article

Trending on BioPharm International

FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies

Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India

Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity

Teva Licenses US Rights to Samsung Bioepis TNF Inhibitor Biosimilars

How Conjugation Changes Antibody Behavior in Solution and at Interfaces